1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature of
the transaction
|
The sale of 1,120 Ordinary Shares to facilitate a transfer into an
ISA
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.88
|
1,120
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature of
the transaction
|
The purchase of 1,112 Ordinary Shares into an ISA
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.8700
|
1,112
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan Jackson
|
|||
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature of
the transaction
|
The sale of 1,120 Ordinary Shares to facilitate a transfer into an
ISA
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.87
|
1,120
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan Jackson
|
|||
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature of
the transaction
|
The purchase of 1,112 Ordinary Shares into an ISA
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.8740
|
1,112
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr Hal Barron
|
|||
b)
|
Position/status
|
Non-Executive Director
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account
following the reinvestment of dividends
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
61
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr Hal Barron
|
|||
b)
|
Position/status
|
Non-Executive Director
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs within Dr Barron's GSK Executive
Supplemental Savings Plan account following the reinvestment of
dividends
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
2,432.6749
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James Ford
|
|||
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/ amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs within Mr Ford's GSK Executive
Supplemental Savings Plan account following the reinvestment of
dividends
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
45.2660
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2024-05-16
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
20, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|